---
{"dg-publish":true,"permalink":"/USMLE/Pharmacology/Antibiotics/","tags":["t1"]}
---

![L43892.jpg](/img/user/appendix/L43892.jpg)
# Penicillin 
---
- **Syphilis (_Treponema pallidum_):**
    
    - **Drug of Choice:** **Penicillin G** is the _only_ effective treatment for all stages, especially neurosyphilis and syphilis in pregnancy.
    - **Regimen:** Single IM dose of Benzathine Penicillin G for primary/secondary syphilis.
- **Streptococcal Pharyngitis (Strep Throat - Group A Strep):**
    
    - **Drug of Choice:** Oral **Penicillin V** or **Amoxicillin** for 10 days.
    - **Key Goal:** Prevent acute rheumatic fever. No known resistance of GAS to penicillin.
- **Rheumatic Fever Prophylaxis:**
    
    - **Drug of Choice:** Long-acting IM **Benzathine Penicillin G** (e.g., every 3-4 weeks) for secondary prevention after an initial episode.
- **Actinomycosis (_Actinomyces israelii_):**
    
    - **Drug of Choice:** High-dose IV **Penicillin G** for an extended period, followed by oral therapy.
    - **Buzzwords:** "Sulfur granules," jaw/cervicofacial abscess.
- **Leptospirosis (_Leptospira_ spp.):**
    
    - **Drug of Choice:** IV **Penicillin G** is used for severe disease.
    - **Presentation:** Flu-like illness, conjunctival suffusion, myalgias, often with animal/water exposure.
- **Meningococcal Disease (_Neisseria meningitidis_):**
    
    - **Drug of Choice:** **Penicillin G** is effective if the isolate is susceptible (though ceftriaxone is often used empirically first).
# Cephalosporins
---
>[!Mnemonic] 
>Cephalosporins are <font color="#ffc000">LAME</font>: 1st–4th generation cephalosporins do not act against 
>- [[USMLE/Infective disease/Listeriosis\|Listeria]]
>- Atypical organisms (e.g., Chlamydia, Mycoplasma)
>	- No cell wall
>- MRSA
>- Enterococci (with the exception of ceftaroline, which does act against MRSA).

---

# Nitrofurans
- Examples: <span style="background:rgba(240, 200, 0, 0.2)">nitrofurantoin</span>
- Mechanism of action: <span style="background:rgba(240, 200, 0, 0.2)">reduced by bacterial nitroreductases to reactive metabolites → bind to bacterial ribosomes → impaired metabolism, impaired synthesis of protein, DNA, and RNA → cell death (bactericidal effect)</span>
- Treatment and prophylaxis of acute uncomplicated <span style="background:rgba(240, 200, 0, 0.2)">UTIs</span> (e.g., urethritis, cystitis)
# Drug resistance
---
## Mechanisms

| **Type of resistance**     | **Example mechanisms**                                                                      | **Example antibiotics affected**                                      |
| -------------------------- | ------------------------------------------------------------------------------------------- | --------------------------------------------------------------------- |
| Increased drug efflux pump | • New membrane transport system                                                             | • Tetracyclines, fluoroquinolones                                     |
| Drug-inactivating enzyme   | • Beta-lactamase<br>• Acetyltransferase                                                     | • Penicillins, cephalosporins<br>• Aminoglycosides                    |
| Decreased drug uptake      | • Mutated porin protein                                                                     | • Penicillins, fluoroquinolones                                       |
| Modified drug target       | • Altered penicillin-binding protein<br>• Altered ribosomal protein<br>• Altered DNA gyrase | • Penicillins<br>• Aminoglycosides, macrolides <br>• Fluoroquinolones |

## Examples
**1. MRSA (Methicillin-Resistant _Staphylococcus aureus_)**

- **Clues:** Purulent skin/soft tissue infections (SSTIs) often looking like "spider bites" (CA-MRSA); hospital-acquired pneumonia, post-op infections, line infections (HA-MRSA). Post-influenza pneumonia.
- **Mechanism:** _mecA_ gene (altered PBP2a).
- **Tx:**
    - **SSTI (CA):** TMP-SMX, Doxycycline, Clindamycin (after I&D).
    - **Severe/Hospital (HA):** Vancomycin, Linezolid, Daptomycin.

**2. VRE (Vancomycin-Resistant Enterococci)**

- **Clues:** UTI, bacteremia in hospitalized patients with prolonged antibiotic use (especially vancomycin/cephalosporins) or indwelling catheters.
- **Mechanism:** D-Ala-D-Ala to D-Ala-D-Lac/Ser.
- **Tx:** Linezolid, Daptomycin. (Nitrofurantoin/Fosfomycin for cystitis if susceptible).

**3. Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales (_E. coli, Klebsiella_)**

- **Clues:** <span style="background:rgba(240, 200, 0, 0.2)">Recurrent UTIs</span> despite cephalosporins; hospital/LTCF-acquired infections (UTI, intra-abdominal).
- **Mechanism:** Beta-lactamases hydrolyzing most penicillins & cephalosporins.
- **Tx:** Carbapenems (Imipenem, Meropenem). (Fosfomycin/Nitrofurantoin for cystitis if susceptible).

**4. CRE (Carbapenem-Resistant Enterobacterales - e.g., _Klebsiella pneumoniae_ carbapenemase/KPC)**

- **Clues:** Critically ill ICU patients; multiple prior antibiotics (including carbapenems); invasive devices. High mortality.
- **Mechanism:** Carbapenemase enzymes.
- **Tx:** Very limited; often combination therapy with newer agents (e.g., Ceftazidime-avibactam, Meropenem-vaborbactam) or Colistin/Tigecycline.

**5. Drug-Resistant _Streptococcus pneumoniae_**

- **Clues:** CAP, meningitis, otitis media failing first-line beta-lactams. Risk factors: age extremes, daycare, recent antibiotics.
- **Mechanism:** <span style="background:rgba(240, 200, 0, 0.2)">Altered PBPs (penicillin resistance)</span>; ribosomal methylation/efflux (macrolide resistance).
- **Tx:**
    - **CAP (non-meningeal):** Respiratory Fluoroquinolones (Levofloxacin, Moxifloxacin), Vancomycin (if severe/highly resistant). Ceftriaxone (if lower-level penicillin resistance).
    - **Meningitis:** Vancomycin + 3rd gen Cephalosporin (e.g., Ceftriaxone).

**6. MDR-TB & XDR-TB (Multidrug/Extensively Drug-Resistant Tuberculosis)**

- **Clues:** Prior TB treatment failure; from high-prevalence area; HIV co-infection; persistent TB symptoms despite standard therapy.
- **MDR:** Resistant to Isoniazid (INH) + Rifampin (RIF).
- **XDR:** MDR + resistance to a fluoroquinolone AND ≥1 injectable second-line drug.
- **Mechanism:** Chromosomal mutations (e.g., _katG_, _rpoB_).
- **Tx:** Complex, prolonged multi-drug regimens with second-line drugs (e.g., Bedaquiline, Linezolid, Fluoroquinolones) based on DST. Expert consultation mandatory.